Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 20 Key Players companies in PCSK9 Inhibitors
by Most News Heat in the United Kingdom in 2019

The PCSK9 Inhibitors top 20 is Discovery PatSnap’ annual ranking of the top 20 Most News Heat PCSK9 Inhibitors Key Players in the United Kingdom. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2019, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
The PCSK9 inhibitors are a class of injectable drugs approved in 2015 that have been shown to dramatically lower LDL cholesterol levels -- by up to 60% in some cases -- when combined with a statin.. PCSK9 inhibitors are monoclonal antibodies (MABs), a type of biologic drug. They bind to and inactivate an enzyme in the liver called proprotein convertase subtilisin kexin 9 (PCSK9).
#
Company Name
Region
Tech Topics
Total
1
Medicine,Health care,Side effect,
...[+2]
news: 16
2
Health care,Clinical trial,Drug,
...[+2]
news: 12
3
Safety monitoring,Contract research organization,Laboratory testing,
...[+2]
news: 12
4
Good manufacturing practice,Pharmaceutical manufacturing,Contract research organization,
...[+2]
news: 7
5
news: 5
6
Humphries Ltd.
news: 4
7
news: 3
8
news: 3
9
news: 3
10
news: 3
11
Evercore ISI International Ltd.
news: 3
12
NHS England
Health care,Public participation,Rigour,
...[+2]
news: 2
13
Technology transfer,Angel investor,Ecosystem,
...[+2]
news: 2
14
RPH Ltd.
news: 2
15
news: 2
16
National Health Service for Scotland
Healthcare system
news: 2
17
news: 1
18
Newton Investment Management Ltd.
Asset management,Insurance broker,Pension
news: 1
19
Hospitality industry,Cloud database,Decision-making
news: 1
20
news: 1
Page generation time: Jun 03 2025